Henry Ford Hospital Medical Journal
Volume 37

Number 1

Article 2

3-1989

Screening for Adenocarcinoma of the Prostate
Brian J. Miles

Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal
Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons

Recommended Citation
Miles, Brian J. (1989) "Screening for Adenocarcinoma of the Prostate," Henry Ford Hospital Medical
Journal : Vol. 37 : No. 1 , 5-7.
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol37/iss1/2

This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has
been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health
System Scholarly Commons.

Screening for Adenocarcinoma of the Prostate
Brian J. Miles, MD*

A

denocarcinoma of the prostate is the second leading cause
of cancer and the third leading cause of death from cancer
in American men. For American black men it is the number one
cause of cancer and death from cancer. The clinical incidence of
carcinoma of the prostate is approximately 69 per 100,000 men,
but the prevalence is between 5% to 40% of men over age 50 (1).
Certainly this makes cancer of the prostate the most prevalent
cancer in males. Unfortunately, over half of the patients presenting with this disease have either significant locally advanced or
metastatic disease.
The need for a screening method for cancer of the prostate has
been recognized for some time and was advocated as early as
1905 by Young (2). However, great care must be exercised when
evaluating the value of any potential screening test. It is far too
easy to become optimistic based on seemingly high sensitivity
and specificity values for a given test. The true usefulness of any
testing modality lies in its "predictive value" (3). Given that a
particular test is positive, the probability that the patient actually
has prostate cancer is its predictive value:

Sensitivity =
#TP + FN

Specificity =

Predictive Value Positive

#TN
#TN + FP

S XP
(S X P) -I- ([1 - SP] X [1 - P])

where TP = true positives, FN = false negatives, TN = true
negatives, FP = false positives, S = sensitivity, P = prevalence, and SP = specificity.
Unfortunately, predictive value is seldom referred to whenever the subject of screening is broached. In prostate cancer, if
predictive values were used they would be questionable because
of the large discrepancy between the prevalence of the disease
and its clinical incidence. Since only one third of the patients
with prostate cancer will ever manifest the disease clinically, the
question is raised as to whether or not we will be screening patients, at considerable expense, who do not need treatment. This
issue is beyond the scope of this brief review but has been
reviewed elsewhere (4).
If we accept "prevalence" as being in the 5% to 40% range,
the predictive value of most modalities discussed herein is still
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not high enough to warrant their consideration as screening
tools. In fact, the American Urologic Association (AUA) recently published a directive strongly discouraging the use
of prostate specific antigen (PSA) and prostate ultrasound
as screening modalities (5). However, these modalities as well
as others are available for the evaluation of adenocarcinoma of
the prostate.

Creatine Kinases/Alkaline Phosphatase
Since Gutman and Gutman (6) discovered the association
between acid phosphatase and adenocarcinoma of the prostate, investigators have been looking for a prostate serum
marker. Potential serum markers that have been evaluated in
the past years include creatine kinase, alkaline phosphatase,
ribonuclease, lactate dehydrogenase isoenzymes, hydroxyproline, polyamines, alfa-fetoprotein, and beta human
chorionic gonadotropin, among others. The best, according
to Fair et al (7), is creatine kinase. This is an enzyme that catalyzes the transfer of a phosphate group from phosphocreatine to adenosine diphosphate. There are three bands
of creatine kinase. The BB band is found exclusively in the
genitourinary system, especially in the cytoplasm of normal
and cancerous prostate tissue. Unfortunately, the sensitivity
is less than 15% and the specificity is approximately 45% in
large clinical trials. Therefore, creatine kinase has limited
value for following patients with known carcinoma of the
prostate and is of no value as a screening tool. The alkaline
phosphatase test has similar problems with sensitivity and
specificity and is of value only for following response to therapy in patients with known disease.

Acid Phosphatase
The acid phosphatases have been the mainstay of serum markers for evaluation of prostate carcinoma since the 1930s when
they were discovered by Gutman and Gutman (6). Acid phosphatase is an enzyme that hydrolyzes phosphate esters at a PH of
< 7.0. They are ubiquitous, being found in serum, red and
white blood cells, the spleen, kidney, bone, and numerous other
organs such as the prostate. In the prostate acid phosphatase is
found in the lysosomal fraction of epithelial cells. Its concentraSubmitted for publication: January I I , 1989.
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don in the prostate is 1,000 times greater than that of any other
organ or cell. Of the nine isoenzymes of acid phosphatase, isoenzyme 2 has the greatest activity in the prostatic acid phosphatase test. Semen is the only tissue fluid with isoenzyme
2 activity.
When the prostate becomes cancerous it retains its ability to
produce acid phosphatase, although the overall tissue concentrations are reduced, as measured by qualitative histochemical
studies. There is a circadian rhythm found in the serum levels of
acid phosphatase in patients with cancer of the prostate but not in
normal patients, necessitating repeated measurements in following patients with known prostate carcinoma.
Prostatic acid phosphatase (PAP) is assayed by numerous
methods including enzymatic studies, radioimmunoassays
(RIAs), counterimmunoelectrophoresis, enzyme-linked immunosorbent assay, andfluorescentimmune antibodies. Much controversy existed in the 1970s regarding RIA versus enzymatic
studies. However, numerous investigators found significant
problems with the specificity and sensitivity of both methods
(8-12). The enzymatic method of detecting acid phosphatase is
very specific but not very sensitive, and the RIA is very sensitive
but much less specific (13). Bruce et al (9) and Cooper and
Finkle (14) confirmed that acid phosphatase levels as determined
by either enzymatic or RIA methods are not effective in distinguishing between benign prostatic hypertrophy (BPH) and
localized adenocarcinoma of the prostate. Therefore, the acid
phosphatases have no value as screening tests. Acid phosphatase
has much more value for following patients with known disease
to evaluate their response to therapy or to predict disease
progression.

Prostate Specific Antigen
Discovered by Wang et al (15) in 1979, PSA is a relatively new
marker for evaluating patients with adenocarcinoma of the prostate. Its concentration is similar in normal, benign, and malignant tissue. This secretory-like protein is found in the seminal
fluid and is a small molecule but highly inmiunogenic. It is entirely different from PAP, and with it either polyclonal or monoclonal antisera are easily generated. PSA is not prostate cancer
specific; it is prostate tissue specific.
PSA is an excellent marker for evaluating patients with known
adenocarcinoma of the prostate, but, as with acid phosphatase,
false elevations occur in patients with BPH and "falsely" normal levels may be obtained in patients with known prostate carcinoma. Ban et al (16) found elevated PSA levels in only 25% of
patients with known carcinoma. Stamey et al (17) recently reported that BPH contributed an average serum level of 0.3 ng/
mL per gram of prostate tissue resected. While this value may be
high, others have found that approximately 20% of patients with
BPH have elevated PSA levels (18-20). As with PAP, the value of
PSA is in following patients with known carcinoma. PSA
should not be utilized as a screening tool. The AUA recently
made the following statement on PSA (5):
Serum PSA is not effective as a screening test for prostate
cancer At present, semm PSA appears to be most useful
for determining the presence of residual cancer after
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abladve surgical procedures and determining early recurrence following radiation therapy, radical surgery, or hormonal therapy. Further study will be required to define
other roles of PSA in prostate cancer patients.

Other Modalities
There are no radiographic studies suitable to use as screening
modalities for carcinoma of the prostate. However, the recent
development of prostatic ultrasound has raised the hope that it
may be useful in this way. Perhaps prostatic ultrasound may become as valuable as the mammogram in females. However, the
high cost of this test and the low clinical incidence of prostate
carcinoma make its usefulness questionable. According to the
AUA (5):
Transrectal prostatic ultrasonography, because of its relative lack of specificity and sensitivity, cannot be recommended for mass screening for carcinoma of the prostate
in asymptomatic male patients.
Transrectal ultrasonography is not recommended for
routine use in the patient who has no symptoms to suggest
prostatic carcinoma, no physicalfindingsof prostatic carcinoma, and/or no laboratory or radiographic evidence of
prostatic carcinoma.
Aspiration cytology and random core needle biopsies of the
prostate could be effective screening tools. However, because of
the invasive nature and possible complications of these tests,
they cannot be used for large-scale unselected population
screening (21).
The digital rectal examination is currently the most effective
screening tool for adenocarcinoma of the prostate. In evaluating
the rectal examination as a screening test for adenocarcinoma of
the prostate, Thompson et al (22) found that screened patients
were discovered at an earlier clinical stage (stage B) than unscreened patients (70% versus 40%, although pathologic downstaging lowered this to 43% versus 28%). As determined by
McNeal et al (23), we can nuss as many as 25% of the padents
with adenocarcinoma of the prostate due to the anterior origin of
this disease. Thus a high index of suspicion and thorough rectal
examination are extremely important. The rectal examinadon is
easy to perform, can be done by all physicians, and therefore
remains the gold standard in screening for prostate carcinoma
(24).
Guinan et al (25) compared five tests for the diagnosis of adenocarcinoma ofthe prostate: aspiration cytology, prostatic ultrasound, acid phosphatase, PSA, and rectal examination. Not the
most rigorous of studies, their results are probably unfairiy
biased against prostatic ultrasound since the transducer used was
only 3'/2 to 4 MHz, well below the capacity of transducers currently in use. The study included 280 men, mean age 68.1 years,
who underwent a transrectal biopsy. Of these patients, 28 had
histologic diagnosis of adenocarcinoma of the prostate. The results ofthe study permitted calculation of relative sensitivity and
specificity values for each modality. The authors developed an
"efficiency coefficient," defined as the percentage of patients
correctly determined to have prostate cancer The formula utilizes prevalence, sensitivity, and specificity:
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(pa -b [1 - p]b) X 100
where a = sensitivity, b = specificity, and p = prevalence (percentage of patients with carcinoma of the prostate in the population studied).
The efficiency coefficients were 63% for aspiration cytology,
71% for prostatic ultrasound, 74% for PSA, 66% for acid phosphatase, and 75% for rectal examination. As evident from these
data, the digital rectal examination was superior to all other
modalities and is the least expensive of these tests. As more
work is completed, prostatic ultrasound may surpass the digital
rectal examination as a screening tool. However, primary care
physicians and urologists should continue to trust a well-performed rectal examination as an effective screening procedure
for adenocarcinoma of the prostate (26). Patients should not be
routinely subjected to PSA, PAP, aspiration biopsy, or ultrasonic
testing until the predictive values of these tests become much
higher.
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